{"filings":[{"id":442796,"accession_number":"0001193125-26-224037","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-05-14T20:13:22+00:00","items":["5.07"],"status":"ready","headline":"Surrozen stockholders elect two Class II directors, ratify EY auditor, approve say-on-pay on annual basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Mace Rothenberg, M.D. (5,982,651 for, 1,107,751 withheld) and David J. Woodhouse (7,087,293 for, 3,109 withheld) as Class II directors.","Ratified Ernst & Young LLP as independent auditor for 2026: 7,744,358 for, 284 against, 27 abstain.","Advisory vote on executive compensation approved: 6,312,815 for, 776,738 against, 849 abstain, 654,267 broker non-votes.","Stockholders preferred annual say-on-pay frequency (7,068,763 votes for 1 year); board adopted annual advisory vote going forward.","Total shares represented at meeting: 7,744,669 of 11,486,707 entitled; no proposals opposed by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95866,"accession_number":"0001193125-26-208999","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.","Cash and equivalents $106.9M as of Mar 31, 2026, up from $89.2M at Dec 31, 2025.","Received $5M milestone payment from Boehringer Ingelheim in April 2026 for SZN-413 GLP toxicology study progress.","On track to submit IND for SZN-8141 for retinal diseases in H2 2026; preclinical data presented at ARVO.","R&D expenses $9.3M (up $2.7M YoY) due to ophthalmology program costs; G&A $6.1M (up $2.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":5000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109251,"accession_number":"0001193125-26-119757","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.","Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).","No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.","Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.","On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109250,"accession_number":"0001193125-26-031798","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Shao-Lee Lin resigns from Surrozen board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shao-Lee Lin, M.D., Ph.D., resigned from the Board on January 26, 2026, effective immediately.","Resignation was not due to any disagreement with the Company's operations, policies or practices.","Surrozen thanks Dr. Lin for her service and dedication to the Company's mission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125744,"accession_number":"0001193125-25-272363","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Surrozen Q3 net loss $71.6M, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.","Revenue fell to $1.0M (all from related party) from $10.0M in Q3 2024, due to absence of Boehringer Ingelheim milestone payment.","Cash $81.3M at Sep 30, 2025 (down from $90.4M at Jun 30); R&D $7.8M vs $5.2M, G&A $4.1M vs $3.6M YoY.","Andrew Maleki appointed CFO effective Nov 12, 2025; Charles Williams continues as COO and Secretary.","Company on track to submit IND for SZN-8141 in 2026; ophthalmology pipeline remains focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":2949000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125743,"accession_number":"0001193125-25-242518","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.","Agreement provided Surrozen up to $6.0M in payments plus warrant for 3.4M TCGFB shares at $0.0001/share.","Collaboration was for antibody discovery services; TCGFB owned all TGF-β product IP.","TCGFB is affiliated with The Column Group, a >5% holder of Surrozen stock; board member Kutzkey is TCG Managing Partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142464,"accession_number":"0000950170-25-112253","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Surrozen enters ATM equity offering agreement for up to $50M with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with TD Securities (USA) LLC to sell up to $50M of common stock at-the-market or in negotiated transactions.","TD Cowen will receive a 3% commission on gross proceeds from shares sold.","Offering is made under existing S-3 registration statement and prospectus supplement dated August 29, 2025.","Surrozen is not obligated to sell any shares; agreement may be terminated by either party on written notice.","Cooley LLP issued a legal opinion on the validity of the shares, filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142463,"accession_number":"0000950170-25-105839","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.","Cash and cash equivalents $90.4M at June 30, 2025, down from $101.6M at March 31, 2025.","Appointed Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development; also formed Clinical Advisory Board with four retinal specialists.","Granted U.S. Patent No. 12,297,278 covering SWAP multi-specific Wnt surrogate technology; IND submission for SZN-8141 targeted for 2026.","R&D expenses $6.0M (up from $5.3M) and G&A $4.0M (up from $3.7M); research service revenue from related party $1.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":1966000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160508,"accession_number":"0000950170-25-072696","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surrozen stockholders elect three Class I directors and ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anna Berkenblit, M.D. elected with 1,351,951 for, 503,791 withheld, 453,045 broker non-votes.","Eric Bjerkholt elected with 1,787,859 for, 67,883 withheld, 453,045 broker non-votes.","Tim Kutzkey, Ph.D. elected with 1,851,021 for, 4,721 withheld, 453,045 broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 2,307,951 for, 0 against, 836 abstain.","No other matters were submitted to a vote; 2,308,787 shares represented (70.4% of eligible)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160507,"accession_number":"0000950170-25-068011","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.","Cash increased to $101.6M from $34.6M at year-end 2024, boosted by $76.4M from first tranche of $175M private placement.","Discontinued SZN-043 for severe alcohol-associated hepatitis due to insufficient Phase 1b benefit; shifted focus to ophthalmology.","Expects to file IND for lead candidate SZN-8141 in 2026; FDA clearance triggers $98.6M tranche to fund operations.","Research service revenue $1.0M from TCGFB collaboration; other income $38.0M from non-cash warrant valuation changes."],"consensus_eps_estimate":-1.8207,"consensus_eps_actual":-7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":983000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178757,"accession_number":"0000950170-25-047702","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.","Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.","Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.","R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.","Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing."],"consensus_eps_estimate":-1.8207,"consensus_eps_actual":-7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":983000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178756,"accession_number":"0000950170-25-046769","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Surrozen raises ~$76.4M in first tranche private placement; appoints Tim Kutzkey to Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First tranche closed March 26, 2025; gross proceeds ~$76.4M from 6,586,415 Units at $11.60 each.","Each Unit includes one share (or pre-funded warrant) and one-half Series E Common Warrant ($11.54 exercise, 5-year term).","Second tranche of up to 8,499,821 Units (~$98.6M) conditioned on FDA IND clearance for SZN-8141 by Oct 31, 2026.","Series C and D warrants cancelled; Series A and B exercise prices reduced to $11.54 (management: $12.45).","Dr. Tim Kutzkey (The Column Group) appointed as Class I director; initial option grant for 2,666 shares at $10.66."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178755,"accession_number":"0001193125-25-061361","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.","Prioritizes ophthalmology pipeline: lead candidates SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6) for retinopathies.","Discontinues SZN-043 in severe alcohol-associated hepatitis due to insufficient clinical benefit signal relative to development path.","Tim Kutzkey, Ph.D. joins Board of Directors; Series A/B warrant exercise prices reduced, Series C/D warrants cancelled.","Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195431,"accession_number":"0000950170-24-121856","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).","Cash $31.0M at Sep 30, 2024; plus $10M milestone received Oct 2024 from Boehringer Ingelheim.","Phase 1b SZN-043 in severe alcohol-associated hepatitis: cohort 1 completed; no SAEs, reduced bilirubin/MELD; PoC data expected H1 2025.","Nominated wholly-owned preclinical ophthalmology candidates SZN-8141/8143/113 targeting Fzd4; SZN-413 advancing with BI.","New TCGFB research collaboration for TGF-β antibodies in IPF; up to $6M plus equity warrant of 3.38M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195430,"accession_number":"0000950170-24-111493","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Surrozen extends HQ lease through April 2029 with escalating rent, $400K early termination option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended 48 months to April 2029; annual base rent starts at $2.3M, rises to $2.6M.","Early termination option (April 2026) requires $400K fee by Dec 31, 2025; notice by Sep 30, 2025.","Extension option reduced from two 5-year to one 4-year option following extended term.","Rent abatement for Jan-Mar 2026 applies if early termination option not exercised.","Amendment updates assignment, net worth, and financial reporting provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211691,"accession_number":"0000950170-24-095414","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.","Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.","R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.","Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.","Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211690,"accession_number":"0000950170-24-079690","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surrozen director Tim Kutzkey resigns from board and committees effective June 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim Kutzkey, Ph.D. resigned as director and from all board committees on June 30, 2024.","Resignation is not due to any disagreement with the company on operations, policies, or practices.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230422,"accession_number":"0000950170-24-070741","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surrozen reports 2024 annual meeting vote results: directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors elected: Christopher Y. Chai, Mary Haak-Frendscho, and Craig Parker.","Christopher Y. Chai: 1,267,311 for, 147,380 withheld; broker non-votes 393,588.","Mary Haak-Frendscho: 1,410,102 for, 4,589 withheld; broker non-votes 393,588.","Craig Parker: 1,409,464 for, 5,227 withheld; broker non-votes 393,588.","Ratification of Ernst & Young as auditor for FY2024: 1,803,744 for, 416 against, 4,119 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230421,"accession_number":"0000950170-24-055667","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.","R&D expense $5.2M (down 36% YoY); G&A $3.9M (down 26% YoY) reflecting 2023 restructuring.","SZN-043 Phase 1a completed; Phase 1b enrollment to begin Q2 2024; proof-of-concept data expected H1 2025.","Potential $10M milestone from Boehringer Ingelheim if lead Fzd-4 Wnt agonist candidate nominated in 2024.","Preclinical data at ARVO on Wnt mimetic for corneal dystrophies; publication on pulmonary fibrosis in Respiratory Research."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230420,"accession_number":"0000950170-24-040337","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Surrozen raises $17.5M in private placement with milestone-triggered warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 1,089,033 shares at $15.50 and pre-funded warrants for 40,000 shares at $15.4999.","Management purchases 2,948 shares at $16.96; total gross proceeds ~$17.5M.","Series A warrants: 1,129,033 shares at $15.50, exercisable for 5 years.","Series B warrants: 1,228,071 shares at $14.25; exercisable after 15-patient enrollment milestone in SZN-043 trial.","Series C/D warrants: each up to 4,375,000 shares at $16.00, exercisable after Phase 1b data or ≥50 patient enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230419,"accession_number":"0000950170-24-038902","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.","Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.","In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.","Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}